Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Rad Laboratories reports robust earnings, eyes growth through new products

Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.

Bio-Rad reports resilient Q1 performance amidst challenges and opportunities

Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.
The impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.
With a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.

Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities

Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.
Despite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.
Anticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.
The company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.

Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth

Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.
Despite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.
Analysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.
The company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.

Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities

Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.
The company faces headwinds in the China market but sees opportunities in new product launches and market recovery.
Financial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.
Guidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.

Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism

Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.

Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints

Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.
Operational improvements and successful share repurchases demonstrate resilience and strategic focus.
Challenges in the Life Science group highlight areas for improvement and strategic decision-making.

Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call

Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.
While facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.
Maintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.
Analyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Bank of New York Mellon

GCI Liberty

Value focused investors may want to consider the following stocks, since their share prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based discounted cash flow calculator.

A Trio of Potential Deals You Shouldn't Miss

As of late, it has definitely been a great time to be an investor in Bio-Rad Laboratories (BIO).

Bio-Rad Laboratories' (BIO) Shares March Higher, Can It Continue?

Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Bio-Rad (BIO) Run Higher on Rising Earnings Estimates?

Bio-Rad's (BIO) third-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Rise

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q3 2020 Results - Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of 62.16% and 14.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Q3 Earnings and Revenues Top Estimates

Shares of Bio-Rad Laboratories (NYSE:BIO) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 86.34% year over year to $3.00, which beat the estimate of $1.80.

Bio-Rad Laboratories: Q3 Earnings Insights

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2020. Third-quarter 2020 net sales were $647.3 million, an increase of 15.5 percent compared to $560.6 million reported for the third quarter of 2019. On a currency-neutral basis, quarterly sales increased 14.9 percent compared to the same period in 2019. Third-qu

Bio-Rad Reports Third-Quarter 2020 Financial Results

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Bio-Rad Laboratories, Inc. (NYSE:BIO) changed recently.

Was The Smart Money Right About Crowding Into Bio-Rad Laboratories, Inc. (BIO)?

Bio-Rad Gains 16.2% Since September, Bullish Outlook Remains Strong

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2020 on Thursday, October 29, 2020, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day. To listen, call 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., passcode: 706113

Bio-Rad to Report Third-Quarter 2020 Financial Results, Thursday, October 29, 2020

DaVita

Molina Healthcare

With four potential Covid-19 vaccine candidates from Moderna Inc. (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), AstraZeneca PLC (NYSE:AZN) and Johnson & Johnson (NYSE:JNJ) now in late-stage human trials, and many others still in development, consumers and investors alike are continuing to carefully watch the health care space.

3 Health Care Companies to Consider as Covid-19 Vaccine Trials Continue

Biogen

CVS Health

Immunomedics

Livongo Health Inc

Moderna

Insulet

Perrigo

QuidelOrtho Corp

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

Top Healthcare Stocks for October 2020

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?

Bio-Rad (BIO) Down 6.9% Since Last Earnings Report: Can It Rebound?

ABIOMED

Danaher

DexCom

Hologic

IDEXX Laboratories

Regeneron Pharmaceuticals

Thermo Fisher Scientific

Vertex Pharmaceuticals

West Pharmaceutical Services

Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.

These 10 Stocks Are the Biggest S&P 500 Healthcare Winners of 2020

FCF has grown 159% YoY, however ROCE remains sluggish at only 3%, which we feel needs evidence of improvement into Q3.

Bio-Rad Laboratories: Poor ROCE Of 3% Hurts Valuation, But The Long-Term Stance Remains

Bio-Rad Laboratories (BIO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Why Bio-Rad Laboratories (BIO) Could Be Positioned for a Surge

Will Bio-Rad (BIO) Gain on Rising Earnings Estimates?

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago.

The United States Court of Appeals for the Federal Circuit Affirms That 10x Genomics Willfully Infringed Bio-Rad U.S. Patent and Upholds Lower Court’s Award of Damages

Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.

Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises

Bio-Rad (BIO) delivered earnings and revenue surprises of 23.85% and 1.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Q2 Earnings and Revenues Surpass Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc.

Bio-Rad Reports Second-Quarter 2020 Financial Results

Baxter

Stryker

Teleflex

Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.

Medical Products Stock Earnings on Jul 30: BAX, SYK & More

Strength in product demand related to COVID-19 testing and research is likely to have aided Bio-Rad's (BIO) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Offing?

To get ready for earnings season, look for stocks in or near a potential buy zone ahead of their next quarterly report. One company that fits that bill is Bio.

News for Bio-Rad Laboratories Stock (BIO)